Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. - Wikidata - awgldk - TriplyDB

Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.

Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.

http://www.wikidata.org/entity/Q36849416

about

Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels UPLC-MS/MS determination of voriconazole in human plasma and its application to a pharmacokinetic study.Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.PharmGKB summary: voriconazole pathway, pharmacokinetics.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.Utility of voriconazole therapeutic drug monitoring: a meta-analysis.Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome.Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.Voriconazole and the liver.Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients.Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?

P2860

Q34020402-82827315-DDBD-45AA-95A9-64DEEE33B552 Q35105949-381D0C8A-C10D-4785-A0DC-C01B52E63C54 Q35169112-9082B61D-9C05-4FC5-9AC2-308CE4C4F4BE Q35187285-D212766D-91CC-4B31-ADD4-25BAF32F4F32 Q35954530-6B61AE39-39E4-4FD9-A6C7-78A2EE338111 Q36608562-D144EBCD-60CE-48F3-80B7-01F3601A2907 Q36887922-DA0ACAE0-D6FF-4E10-BAA6-FF596643660E Q37152418-54FF48E8-6448-411D-88C7-21A2A232AECF Q37693296-F8538923-4C56-4C02-BF28-C9AF0BEDF234 Q38211509-5A3378B7-AB65-495D-9FE2-9B80660D71F5 Q38362057-2E3D072E-ADAB-4628-8A8E-95EEF33AA9FB Q38526795-39AF776F-14DD-48E4-B3E3-557B453F42B0 Q38690098-0EC81F5F-11F1-41F3-94C7-A3AF9EEF1B05 Q38918175-C28C541C-CB63-4A49-9D71-1F14041D173B Q39196770-37C899A5-D16A-4E0D-8699-F1C064AEF3F5 Q39479653-DFA75178-CAC8-42B9-9135-589C9FC79262 Q40679884-521771C3-525C-48A4-A7BC-B384B835F368 Q40762430-917FC1FC-5FD8-4F68-A89D-2F1F3D053207 Q41284722-0E9BD0D9-8811-4ADA-B9E4-3021F02BCA66 Q42027433-A50908CD-E477-460A-A9E2-EB313195C6F2 Q42269872-1038395C-952F-4AE5-BED4-4AFADEB81D6E Q49385523-95EA6E63-4D37-4156-8236-6C4D2AC27301

P2860

Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.

http://www.wikidata.org/entity/Q36849416

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Voriconazole therapeutic drug ...... l outcomes and adverse events.

@en

type

label

Voriconazole therapeutic drug ...... l outcomes and adverse events.

@en

prefLabel

Voriconazole therapeutic drug ...... l outcomes and adverse events.

@en

P1433

Q36849416-3F1976B5-B6E3-481A-AA44-545FDAEF9CD7

P1476

Q36849416-969D9C74-2D20-4E3D-A5A2-ACFCAC6FDCDD

P2093

Q36849416-02F50E76-F5F9-4F63-80C3-8F88AF8BC9D0

Q36849416-4164B19E-6CC1-481F-A6B0-657CD790E854

Q36849416-6C480D36-65A9-46B0-8A64-3B480485964A

Q36849416-CC0CB857-168E-43F0-B3ED-1D505B999A7E

P2860

Q36849416-058C9C34-9B0F-4F83-BA3A-32451C14A994

Q36849416-180F5E27-EADB-4979-A4A5-525C2B4E2485

Q36849416-1EA31CF0-9F16-430F-8709-F04F75A46DF6

Q36849416-1FEB75F7-4787-45FC-B545-EEA1AE0EEE96

Q36849416-21F3E9CE-4D78-4D0E-B473-2155C2B276DA

Q36849416-2B431094-CD6E-4075-89EC-3645BC73B040

Q36849416-2B974510-395D-4B6C-8B56-E5203950CC77

Q36849416-2F5692BA-B2B6-4E18-B3A1-8286ED862781

Q36849416-2FD4F436-D518-43E4-9494-F6A2A53BBDBB

Q36849416-2FE3A2E9-F249-467A-B38C-CD135D597D91

P2888

Q36849416-2F7A00FB-EA7C-4EEB-A9EA-39A2761E51A8

P304

Q36849416-F7EB6BAC-F141-4A18-8455-1594F6CC2DE8

P31

Q36849416-61C57A4A-7349-42D1-BE25-4EB03E679B80

P356

Q36849416-87748A94-CB60-4515-B254-ABCCA6A8469C

P478

Q36849416-0988BB8A-3515-4F1F-B664-E61C7EE316E1

P50

Q36849416-72DEA635-5D42-4D2C-8FD0-3E46C2709C5F

P577

Q36849416-FBD10D94-CE3B-483B-AF19-C18779F1C8FF

P5875

Q36849416-E653A18E-B883-42C4-9222-3FFDF415E986

P6179

Q36849416-A7D9F3FF-ADBF-4C0C-A169-21AA75F8C440

P698

Q36849416-137436F5-86F9-4E00-8FC7-414C2F404C04

P932

Q36849416-A6B0178C-61DC-4A22-A23A-5CEB9FFC6EBC

P356

1471-2334-13-105

P1433

BMC Infectious Diseases

P1476

Voriconazole therapeutic drug ...... l outcomes and adverse events.

@en

P2093

Helen Y Chu

http://www.w3.org/2001/XMLSchema#string

Hu Xie

http://www.w3.org/2001/XMLSchema#string

Paul Pottinger

http://www.w3.org/2001/XMLSchema#string

Rupali Jain

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

Voriconazole pharmacokinetics in liver transplant recipients.

Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections

Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.

P2888

1471-2334-13-105

P304

105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-13-105

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

David N Fredricks

P577

2013-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235739323

http://www.w3.org/2001/XMLSchema#string

P6179

1023825382

http://www.w3.org/2001/XMLSchema#string

P698

23442261

http://www.w3.org/2001/XMLSchema#string

P932

3655856

http://www.w3.org/2001/XMLSchema#string